Studies have shown that Ectoin-containing nasal spray and eye drops significantly reduce symptoms of acute allergic rhinitis and conjunctivitis.

A two-week crossover study on 50 patients with acute allergic rhinitis indicated that Ectoin allergy nasal spray, produced by Germany-based bitop AG, is more effective at alleviating symptoms of allergic rhinitis compared with cromoglycinate nasal spray.

Another clinical trial on eye drops and nasal spray in humans had also been conducted using an environmental exposure chamber (EEC) model.

Preliminary results of the EEC study also showed that Ectoin allergy nasal spray is better tolerated than cromoglycinate spray and no adverse reactions were reported.